This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
Corners you can’t see, kerbs you need to kiss, and compromises you must make at the Circuit of the Americas. Aston Martin Aramco Team Ambassador Pedro de la Rosa shares an unparalleled insight into the engineering, technical, and physical…
Shortly after its addition of direct messages this summer, Instagram Threads is adding support for group messaging with up to 50 people. The Meta-owned competitor to X, which now has more than 400 million monthly active users, is making group…
A new study published in Nutrients has shown that daily 5-hydroxytryptophan (HTP) supplementation can improve older adults’ cognitive test scores and mood.
In a 12-week, randomised controlled…
For many companies, relocating pharmaceutical production capacities back to Europe is becoming a key strategic success factor. Saltigo, LANXESS`s exclusive synthesis subsidiary, helps pharmaceutical manufacturers strengthen their supply chains, meet regulatory requirements, and achieve sustainability goals in production. At CPHI Frankfurt 2025 (October 28-30 at the Messe Frankfurt), Saltigo will present solutions that will enable pharmaceutical companies to strengthen their supply chains through targeted reshoring, minimize regulatory risks, and produce more sustainably.
The European pharmaceutical industry is facing growing dependencies on Asia. China and India dominate the market for active pharmaceutical ingredients (API`s) and many of their precursors. This market concentration poses significant supply risks, particularly in the event of geopolitical tensions, export restrictions, or disruptions to global supply chains. To increase supply and production security, the European Union has launched several initiatives in recent years. These include the Critical Medicines Alliance, established in 2024, and the Strategic Report on Medicines Supply, released in February 2025. These initiatives aim to bolster the European production of critical medicines and their precursors, securing Europe`s long-term strategic independence in the pharmaceutical sector.
New platforms, such as the European Shortage Monitoring Platform (ESMP), and guidelines for preventing bottlenecks enable the EU to establish more resilient supply chain structures. For the industry, diversifying manufacturing locations is becoming a strategic priority, especially for regulatory starting materials (RSM`s) and complex intermediates, which often cause bottlenecks in the value chain.
Saltigo positions itself as a reliable partner for customized chemical syntheses and scalable production solutions in Europe. With sites in Leverkusen and Dormagen, Saltigo offers manufacturing in multipurpose facilities that combine the highest regulatory standards, short delivery routes, strict IP protection, and flexible capacities. Global raw material sourcing within the Group complements this setup of Western supply chains, ensuring more stable processes, lower costs, and shorter time-to-market.
Speed and scalability are decisive advantages. Saltigo can assess new projects technically within a few days and provide initial price estimates. This alleviates short-term bottlenecks in API production.
Saltigo`s technological spectrum includes advanced processes such as olefin metathesis, high-pressure hydrogenation, fluorine and phosgene chemistry, and continuous processes (flow chemistry). Close integration of process development, piloting, and commercial manufacturing enables efficient project transfer from laboratory to large-scale production.
In addition to technological expertise, Saltigo is committed to transparency in its product carbon footprint (PCF). PCF data is available for many products, and the company develops net-zero routes for CO₂-neutral production upon request. In this way, Saltigo contributes to the climate goals of the pharmaceutical industry and strengthens the competitiveness of European supply chains.
At CPHI 2025, Saltigo invites employees of pharmaceutical companies and CDMO to learn about the latest technologies and services and discuss individual projects. “We support our pharmaceutical industry partners when their plants reach capacity limits or when they want to focus on high-value API synthesis,” emphasizes Christoph Schaffrath, Saltigo`s Head of Marketing and Sales.
Interested visitors can find Saltigo at CPHI Frankfurt 2025 in Hall 4.1, Booth K27. Appointments with experts can be arranged in advance or during the trade fair.
Further information about the trade fair can be found at https://lanxess.com/en/company/corporate-structure/subsidiaries/saltigo/cphi.
More than 180,000 People of Tomorrow from over 100 countries gathered in Itu, São Paulo, to celebrate LIFE during Tomorrowland Brasil 2025.
The fifth Brazilian edition of Tomorrowland brought three unforgettable days of music, unity, and…
The day Microsoft officially ended support for Windows 10 has coincided with a Patch Tuesday update, with several zero-day flaws that attackers could exploit to target the older Windows operating system.
Among these is CVE-2025-24990, which…
“With this transaction, we were able to successfully support our client legally thanks to our extensive expertise and many years of experience in advising battery storage projects. The transaction highlights the strong interest in high-capacity energy storage in Germany,” comments Holger Engelkamp, lead partner at Baker McKenzie.
Claire Dietz-Polte, also lead partner, adds: “Our team has been advising investors and developers in the battery storage sector since 2020. The flexibility provided by storage is essential for the expansion of renewable energy in Germany. The scale of projects continues to grow – this transaction also includes large-scale batteries.”
“Battery storage at this scale is essential for Europe’s energy transition,” said Willem-Jan Schutte, CEO of Return. “With these strategically located sites, we are strengthening grid stability and accelerating the shift away from fossil fuels. We appreciate Baker McKenzie’s support in helping us move this transaction forward.”
Return is a leading independent European energy storage provider, with full ownership and control of advanced BESS systems that delivers intelligent renewable integration and strengthens the grid. The new sites are part of the company’s pan-European growth strategy. With an active development portfolio of over 8 gigawatts (GW) and plans to deliver around 5 GW of capacity by 2030, Return continues to strengthen grid stability and reduce dependence on fossil fuels across key European markets.
BESSMART Energies GmbH, based in Berlin, is an independent developer of battery storage systems with extensive experience in infrastructure and renewable energy sectors.
Baker McKenzie’s Energy and Infrastructure practice regularly advises utilities, infrastructure funds, industrial companies, developers and banks on battery storage investments and project development. Baker McKenzie advices throughout the project life cycle, including land securing, planning and permitting, EPC,O&M and marketing agreements, as well as financing.
Legal adviser to Return:
Baker McKenzie
Lead:
Projects/Energy & Infrastructure: Dr. Claire Dietz-Polte (Partner, Berlin)
Corporate/Energy & Infrastructure: Holger Engelkamp (Partner, Berlin)
Team:
Projects/Energy & Infrastructure: Dr. Janet Butler (Counsel), Dr. Maximilian Voll (Counsel), Nico Ruepp (Associate, all Berlin)
Corporate/Energy & Infrastructure: Ben Boi Beetz (Senior Associate, Berlin)
After two FP1 appearances at the Abu Dhabi Grand Prix, Pato was unleashed around his home circuit in Mexico City last year. Watched by a jubilant, packed-out home crowd, driving the MCL38 around the Autódromo Hermanos…